X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (130361) 130361
Newsletter (559) 559
Newspaper Article (409) 409
Book / eBook (195) 195
Book Chapter (104) 104
Magazine Article (85) 85
Dissertation (43) 43
Conference Proceeding (32) 32
Government Document (14) 14
Publication (11) 11
Web Resource (9) 9
Streaming Video (5) 5
Book Review (4) 4
Transcript (3) 3
Trade Publication Article (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (117408) 117408
oncology (56370) 56370
female (48042) 48042
animals (44741) 44741
cancer (44402) 44402
cell line, tumor (38783) 38783
male (31002) 31002
apoptosis (27118) 27118
chemotherapy (26710) 26710
mice (25580) 25580
antineoplastic agents - pharmacology (24431) 24431
middle aged (21403) 21403
apoptosis - drug effects (20608) 20608
expression (19340) 19340
drug resistance, neoplasm (19339) 19339
antineoplastic agents - therapeutic use (18191) 18191
aged (18070) 18070
tumors (17511) 17511
research (16991) 16991
care and treatment (16447) 16447
adult (16346) 16346
cell proliferation - drug effects (15724) 15724
pharmacology & pharmacy (15298) 15298
drug resistance (15209) 15209
breast cancer (14149) 14149
neoplasms - drug therapy (14021) 14021
cell biology (13164) 13164
health aspects (12889) 12889
metastasis (12780) 12780
proteins (12645) 12645
treatment outcome (12561) 12561
analysis (12393) 12393
biochemistry & molecular biology (11924) 11924
cancer therapies (11661) 11661
resistance (11562) 11562
gene expression (11032) 11032
breast neoplasms - drug therapy (11005) 11005
signal transduction - drug effects (10758) 10758
therapy (10728) 10728
drug therapy (10654) 10654
cell survival - drug effects (10636) 10636
antineoplastic combined chemotherapy protocols - therapeutic use (10154) 10154
tumor cells, cultured (10140) 10140
mice, nude (9500) 9500
mutation (9470) 9470
signal transduction (9446) 9446
xenograft model antitumor assays (9420) 9420
prognosis (9375) 9375
drug resistance, neoplasm - drug effects (9292) 9292
kinases (9239) 9239
medicine & public health (9138) 9138
activation (9011) 9011
drug resistance, neoplasm - genetics (8865) 8865
genetic aspects (8864) 8864
dose-response relationship, drug (8755) 8755
growth (8526) 8526
cells (8447) 8447
gene expression regulation, neoplastic - drug effects (8424) 8424
breast neoplasms - pathology (8371) 8371
in-vitro (8211) 8211
research article (8181) 8181
survival (8099) 8099
inhibition (8071) 8071
medicine (8016) 8016
hematology (7841) 7841
breast-cancer (7494) 7494
lung neoplasms - drug therapy (7431) 7431
carcinoma (7111) 7111
cell cycle (6991) 6991
development and progression (6940) 6940
gene expression regulation, neoplastic (6939) 6939
phosphorylation (6855) 6855
multidisciplinary sciences (6792) 6792
antineoplastic agents (6786) 6786
aged, 80 and over (6715) 6715
cell proliferation (6610) 6610
medicine, research & experimental (6517) 6517
cancer research (6456) 6456
cisplatin (6425) 6425
cytotoxicity (6356) 6356
lung cancer (6292) 6292
breast neoplasms - metabolism (6274) 6274
hematology, oncology and palliative medicine (6260) 6260
neoplasms - pathology (6146) 6146
drug synergism (5959) 5959
antimitotic agents (5950) 5950
antineoplastic agents - administration & dosage (5794) 5794
blotting, western (5728) 5728
studies (5719) 5719
physiological aspects (5675) 5675
neoplasms - metabolism (5642) 5642
mice, inbred balb c (5571) 5571
drugs (5474) 5474
biology (5439) 5439
prostate cancer (5365) 5365
patients (5326) 5326
medical research (5287) 5287
angiogenesis (5252) 5252
flow cytometry (5182) 5182
colorectal cancer (5171) 5171
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (44) 44
Online Resources - Online (13) 13
Collection Dvlpm't (Acquisitions) - Vendor file (10) 10
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (10) 10
UofT at Mississauga - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
New College (Ivey) - Stacks (2) 2
Credit Valley Hospital - Stacks (1) 1
Gerstein Science - Circulation Desk (1) 1
Lakeridge Health Sciences - Online (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (130224) 130224
Chinese (1054) 1054
Japanese (710) 710
Russian (257) 257
German (253) 253
French (242) 242
Spanish (73) 73
Polish (59) 59
Hungarian (30) 30
Italian (27) 27
Czech (20) 20
Portuguese (14) 14
Swedish (9) 9
Dutch (8) 8
Turkish (8) 8
Norwegian (7) 7
Ukrainian (7) 7
Danish (5) 5
Korean (5) 5
Hebrew (4) 4
Romanian (3) 3
Lithuanian (2) 2
Slovak (2) 2
Amharic (1) 1
Arabic (1) 1
Bosnian (1) 1
Bulgarian (1) 1
Croatian (1) 1
Kurdish (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Nature (London), ISSN 1476-4687, 2015, Volume 520, Issue 7547, pp. 368 - 372
Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer(1,2... 
CNS CELL-TYPES | MELANOMA | METASTASIS | MICROENVIRONMENT | TRANSLATIONAL PROFILING APPROACH | MULTIDISCIPLINARY SCIENCES | RAF INHIBITOR RESISTANCE | ACQUIRED-RESISTANCE | KINASE INHIBITORS | DRUG-RESISTANCE | CANCER CHEMORESISTANCE | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Clone Cells - drug effects | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Proto-Oncogene Proteins c-fos - deficiency | Adenocarcinoma - metabolism | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Proto-Oncogene Proteins c-akt - metabolism | Melanoma - metabolism | Tumor Microenvironment - drug effects | Cell Survival - drug effects | ErbB Receptors - antagonists & inhibitors | Melanoma - pathology | Down-Regulation - drug effects | Enzyme Activation - drug effects | Adenocarcinoma - drug therapy | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Cell Movement - drug effects | Animals | Clone Cells - pathology | Metabolome - drug effects | Signal Transduction - drug effects | Neoplasm Metastasis - pathology | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Pharmaceutical research | Care and treatment | Oncology, Experimental | Dosage and administration | Research | Drug therapy | Drug resistance | Antineoplastic agents | Tumors | Cancer | Melanoma | Mutation | Metastasis | Kinases | Cancer therapies
Journal Article
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
Seminars in Oncology, ISSN 0093-7754, 2015, Volume 42, Issue 6, pp. 801 - 819
.... Most of these molecular alterations promote multiple steps of carcinogenesis in FGFR oncogene-addicted cells, increasing cell proliferation, angiogenesis, and drug resistance... 
BREAST-CANCER | LUNG-CANCER | IN-VITRO | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | RESISTANCE | GENE AMPLIFICATION | POTENTIAL THERAPEUTIC TARGET | PROGNOSTIC-SIGNIFICANCE | ANTITUMOR-ACTIVITY | EXPRESSION | Neoplasms - metabolism | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Brain Neoplasms - pathology | Fibroblast Growth Factors - genetics | Brain Neoplasms - metabolism | Head and Neck Neoplasms - metabolism | Breast Neoplasms - metabolism | Fibroblast Growth Factors - metabolism | Gastrointestinal Neoplasms - pathology | Glioblastoma - genetics | Receptors, Fibroblast Growth Factor - genetics | Female | Glioblastoma - metabolism | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Gastrointestinal Neoplasms - metabolism | Biomarkers, Tumor - analysis | Head and Neck Neoplasms - drug therapy | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Thoracic Neoplasms - pathology | Brain Neoplasms - genetics | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Thoracic Neoplasms - metabolism | Head and Neck Neoplasms - pathology | Neoplasms - drug therapy | Breast Neoplasms - genetics | Thoracic Neoplasms - genetics | Breast Neoplasms - pathology | Glioblastoma - pathology | Receptors, Fibroblast Growth Factor - metabolism | Head and Neck Neoplasms - genetics | Fibroblast Growth Factors - antagonists & inhibitors | Thoracic Neoplasms - drug therapy | Glioblastoma - drug therapy | Neoplasms - pathology | Drug Resistance, Neoplasm - physiology | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Nature (London), ISSN 1476-4687, 2016, Volume 534, Issue 7605, pp. 129 - 132
...(1,2), but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor(3,4... 
CELL LUNG-CANCER | EGFR KINASE | GROWTH-FACTOR RECEPTOR | TARGETED THERAPIES | GEFITINIB | ACTIVATION | MECHANISM | MULTIDISCIPLINARY SCIENCES | MUTATIONS | AZD9291 | Lung Neoplasms - drug therapy | Drug Resistance, Multiple - drug effects | Protein Conformation - drug effects | ErbB Receptors - genetics | Lung Neoplasms - pathology | Antineoplastic Agents - pharmacology | Benzeneacetamides - pharmacology | Mutant Proteins - antagonists & inhibitors | Disease Models, Animal | Allosteric Regulation - drug effects | Carcinoma, Non-Small-Cell Lung - pathology | Drug Resistance, Multiple - genetics | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Lung Neoplasms - enzymology | Allosteric Site - drug effects | Mutant Proteins - genetics | Cetuximab - pharmacology | Mutant Proteins - metabolism | Drug Synergism | Drug Resistance, Neoplasm - genetics | Animals | ErbB Receptors - chemistry | Mutant Proteins - chemistry | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Protein Multimerization - drug effects | Drug Resistance, Neoplasm - drug effects | Studies | Phosphorylation | Nuclear magnetic resonance--NMR | Epidermal growth factor | Mutation | Kinases | Enzyme kinetics | Tumors
Journal Article
Journal Article
Nature (London), ISSN 1476-4687, 2016, Volume 539, Issue 7629, pp. 443 - 447
Journal Article
Nature (London), ISSN 1476-4687, 2013, Volume 497, Issue 7447, pp. 108 - 112
Cancers acquire resistance to systemic treatment as a result of clonal evolution and selection(1,2... 
HETEROGENEITY | LUNG-CANCER | ACTIVATION | EVOLUTION | VARIANTS | AXL | MULTIDISCIPLINARY SCIENCES | TAMOXIFEN RESISTANCE | TUMOR-CELLS | MUTATIONS | Lung Neoplasms - drug therapy | Genomics | Humans | ErbB Receptors - genetics | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Ovarian Neoplasms - genetics | Neoplasms - genetics | DNA Mutational Analysis | Female | Antineoplastic Agents - pharmacology | DNA, Neoplasm - analysis | Ovarian Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Intercellular Signaling Peptides and Proteins - genetics | Breast Neoplasms - drug therapy | Genome, Human - genetics | Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Drug Resistance, Neoplasm - genetics | Exome - genetics | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Retinoblastoma Protein - genetics | Plasma - chemistry | Alleles | Carcinoma, Non-Small-Cell Lung - drug therapy | DNA, Neoplasm - genetics | Neoplasms - pathology | Mediator Complex Subunit 1 - genetics | Drug Resistance, Neoplasm - drug effects | Evolution, Molecular | Antimitotic agents | Care and treatment | Physiological aspects | Dosage and administration | Genetic aspects | Research | Nucleotide sequencing | Drug resistance | Antineoplastic agents | DNA sequencing | Blood plasma | Cancer | Plasma | Biopsy | Breast cancer | Genomes | Mutation | Patients | Deoxyribonucleic acid--DNA | Tumors
Journal Article